According to some experts, weight-loss drugs could soon be as commonplace as cholesterol-lowering statins. That might sound dramatic, but the numbers suggest otherwise. Between early 2024 and early 2025, according to a new study by University College London, an estimated 1.6m UK adults used weight-loss drugs. (For comparison, about 8m UK adults were prescribed statins over the same period.)Brands such as Ozempic and Mounjaro are fuelling a booming global industry. Morgan Stanley research estimates the global obesity drug market could reach US$150bn at its peak by 2035, up from a previous forec
If you work for any of the following corporate subscribers to Global Drinks Intel, head here to activate your access.
This article is available to Global Drinks Intel members only.
Click below for details on how to join the Global Drinks Intel community.
Already a member?
Log in here to read the article in full.
If you work for any of the following corporate subscribers to Global Drinks Intel, head here to activate your access.
- AB InBev
- Bacardi
- Campari Group
- Diageo
- Moët Hennessy
- Pernod Ricard
- Proximo Spirits
- Suntory Global Spirits
- William Grant & Sons
